Alzheimer Disease as a Clinical-Biological Construct—An International

lion

[size=7.4835pt]IMPORTANCE [size=8.4813pt]Since 2018, a movement has emerged to define Alzheimer disease (AD) as a
[size=8.4813pt]purely biological entity based on biomarker findings. The recent revision of the Alzheimer
[size=8.4813pt]Association (AA) criteria for AD furthers this direction. However, concerns about a purely
[size=8.4813pt]biological definition of AD being applied clinically, the understanding of AD by society at large,
[size=8.4813pt]and the translation of blood-based biomarkers into clinical practice prompt these
[size=8.4813pt]International Working Group (IWG) updated recommendations.